Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875596 | 0.86 | KIF11 (0.49) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| SCHEMBL28856967 | 0.85 | KIF11 (0.47) | KIF11PTGS2 | |
| SCHEMBL1190580 | 0.85 | KIF11 (0.47) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| SCHEMBL31716134 | 0.83 | KIF11 (0.46) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| Hydrochloric Acid SCHEMBL29843373 | 0.83 | KIF11 (0.46) | KIF11PTGS2 | |
| SCHEMBL1191536 | 0.83 | KIF11 (0.46) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| SCHEMBL13995352 | 0.82 | NR1H2 (0.48) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| SCHEMBL13995384 | 0.81 | KIF11 (0.44) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| SCHEMBL13995366 | 0.80 | KIF11 (0.43) | KIF11NR1H2NR1H3PTGDR2HRH4 | |
| SCHEMBL3714911 | 0.78 | HTR2A (0.37) | KIF11CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | claimed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | claimed |
| WO-2010096722-A1 | 3-OXO-2, 3-DIHYDRO- [1,2, 4] TRIAZOLO [4, 3-A]PYRIDINES AS SOLUBLE EPOXIDE HYDROLASE (SEH) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | WO | claimed |
| CN-110467612-B | Simple preparation method of prostaglandin D2 receptor inhibitor compound | 新发药业有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| EP-3356329-B1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-3356329-B1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-3606924-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | disclosed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | disclosed |
| CN-110467612-A | A kind of simple and convenient process for preparing of prostaglandin D 2 receptor inhibitor compound | XINFA PHARMACEUTICAL CO LTD | 2019-11-19 | — | — | CN | disclosed |
| WO-2018178926-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2018-10-04 | — | — | WO | disclosed |
| US-20180273530-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2018-09-27 | — | — | US | disclosed |
| EP-3356329-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| WO-2010096722-A1 | 3-OXO-2, 3-DIHYDRO- [1,2, 4] TRIAZOLO [4, 3-A]PYRIDINES AS SOLUBLE EPOXIDE HYDROLASE (SEH) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | MMAB, PAH, CPS1 | KIF11 353/4885NR1H2 4840/4885NR1H3 4832/4885 |
| US-20180273530-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | MMAB, PAH, CPS1 | KIF11 353/4885NR1H2 4840/4885NR1H3 4832/4885 |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | MMAB, PAH, CPS1 | KIF11 353/4885NR1H2 4840/4885NR1H3 4832/4885 |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | MMAB, PAH, CPS1 | KIF11 353/4885NR1H2 4840/4885NR1H3 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.